PALO ALTO, Calif. & NEW YORK–(BUSINESS WIRE)–GondolaBio, a clinical-stage biopharmaceutical company developing novel medicines for patients living with genetic diseases, and the Children’s Tumor Foundation (CTF), NF’s global drug discovery engine focused on neurofibromatosis and schwannomatosis (collectively known as NF), today announced a partnership to advance GondolaBio’s preclinical neurofibromatosis type 1 (NF1) program. CTF will provide guidance as GondolaBio’s NF1 program advances thro

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.